Cancer feature: cnaPANCAN363

AAR2 ACSS2 ACTL10 AHCY ASIP ASXL1 BCL2L1 BPIFA1 BPIFA2 BPIFA3 BPIFB1 BPIFB2 BPIFB3 BPIFB4 BPIFB6 C20orf112 C20orf144 C20orf173 C20orf24 CBFA2T2 CCM2L CDK5RAP1 CEP250 CHMP4B CNBD2 COMMD7 COX4I2 CPNE1 DEFB115 DEFB116 DEFB118 DEFB119 DEFB121 DEFB123 DEFB124 DLGAP4 DNMT3B DSN1 DUSP15 DYNLRB1 E2F1 EDEM2 EFCAB8 EIF2S2 EIF6 EPB41L1 ERGIC3 FAM83C FOXS1 GDF5 GDF5OS GGT7 GSS HCK HM13 ID1 ITCH KIF3B MAP1LC3A MAPRE1 MMP24 MYH7B MYL9 MYLK2 NCOA6 NDRG3 NECAB3 NFS1 PDRG1 PHF20 PIGU PLAGL2 POFUT1 PROCR PXMP4 RALY RBM12 RBM39 REM1 ROMO1 RP11-410N8.4 RP1-309K20.6 SAMHD1 SCAND1 SLA2 SNTA1 SOGA1 SPAG4 SUN5 TGIF2 TGIF2-C20orf24 TLDC2 TM9SF4 TP53INP2 TPX2 TRPC4AP UQCC1 XKR7 ZNF341

Known Driver Genes: ASXL1

Copy number alternation: gain

Bleomycin (50 uM)

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer